Alliqua BioMedical, Inc. Announces Preliminary Second Quarter of Fiscal Year 2016 Revenue; Earnings Conference Call Scheduled...
July 07 2016 - 7:20AM
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the
Company"), a provider of advanced wound care products, today
announced preliminary second quarter of fiscal year 2016 revenue
results and timing and details of the second quarter financial
results conference call.
Second Quarter Preliminary Revenue
Estimate:
While the Company has not finalized its full
financial results for the six month period ending June 30, 2016, it
expects second quarter total revenue of approximately $5.4 million,
representing growth of approximately 72% year-over-year. The
Company further estimates that sales of wound care products
increased approximately 73% year-over-year to approximately $4.6
million and that contract manufacturing sales were approximately
$800,000 for the second quarter of 2016.
The financial information presented above is a
preliminary estimate only, has not been reviewed by the Company's
independent registered accounting firm and is subject to change
upon completion of the review of the Company’s financial statements
as of and for the quarter ended June 30, 2016. Additional
information and disclosures would be required for a more complete
understanding of the Company’s financial position and results of
operations as of June 30, 2016.
Second Quarter Fiscal 2016 Financial
Results Conference Call:
Chief Executive Officer, David Johnson, and Chief
Financial Officer, Brian Posner, will host a teleconference at 8:00
a.m. Eastern Time on August 9th to discuss the results of the
quarter and to host a question and answer session. Those interested
in participating on the call may dial 888-452-4023 (719-325-2455
for international callers) and provide access code 9341399
approximately 10 minutes prior to the start time. A live webcast of
the call will be made available on the investor relations section
of the Company’s website at http://ir.alliqua.com.
For those unable to participate, a replay of the
call will be available for two weeks at 888-203-1112 (719-457-0820
for international callers); access code 9341399. The webcast will
be archived on the investor relations section of Alliqua’s
website.
About Alliqua BioMedical, Inc.
Alliqua is a provider of advanced wound care
solutions, committed to restoring tissue and rebuilding lives.
Through its sales and distribution network, together with its
proprietary products, Alliqua provides a suite of technological
solutions to enhance the wound care practitioner's ability to deal
with the challenges of healing both chronic and acute wounds.
Alliqua currently markets its line of dressings for wound care
under the SilverSeal® and Hydress® brands, as well as the sorbion
sachet S® and sorbion sana® wound care products, and its TheraBond
3D® advanced dressing which incorporates the TheraBond 3D®
Antimicrobial Barrier Systems technology. The Company's Mist
Therapy System® uses painless, noncontact low-frequency ultrasound
to stimulate cells below the wound bed to promote the healing
process. Alliqua also markets the human biologic wound care product
Biovance®.
In addition, Alliqua can provide a custom
manufacturing solution to partners in the medical device and
cosmetics industry, utilizing its hydrogel technology. Alliqua's
electron beam production process, located at its 16,500 square foot
Good Manufacturing Practice (GMP) manufacturing facility, allows
Alliqua to custom manufacture a wide variety of hydrogels.
Alliqua's hydrogels can be customized for various transdermal
applications to address market opportunities in the treatment of
wounds as well as the delivery of numerous drugs or other agents
for pharmaceutical and cosmetic industries. The Company has
locations in Yardley, PA, Langhorne, PA and Eden Prairie, MN.
For additional information, please visit
http://www.alliqua.com. To receive future press releases via email,
please visit http://ir.stockpr.com/alliqua/email-alerts.
Legal Notice Regarding Forward-Looking
Statements:
This release contains forward-looking statements.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous factors and uncertainties outside of our
control that can make such statements untrue, including, but not
limited to, the adequacy of the Company’s liquidity to pursue its
complete business objectives; inadequate capital; the Company’s
ability to obtain reimbursement from third party payers for its
products; loss or retirement of key executives; adverse economic
conditions or intense competition; loss of a key customer or
supplier; entry of new competitors and products; adverse federal,
state and local government regulation; technological obsolescence
of the Company’s products; technical problems with the Company’s
research and products; the Company’s ability to expand its business
through strategic acquisitions; the Company’s ability to integrate
acquisitions and related businesses; price increases for
supplies and components; and the inability to carry out research,
development and commercialization plans. In addition, other
factors that could cause actual results to differ materially are
discussed in our filings with the SEC, including our most recent
Annual Report on Form 10-K filed with the SEC, and our most recent
Form 10-Q filings with the SEC. Investors and security holders are
urged to read these documents free of charge on the SEC's web site
at http://www.sec.gov. We undertake no obligation to publicly
update or revise our forward-looking statements as a result of new
information, future events or otherwise.
Investor Relations:
Westwicke Partners on behalf of Alliqua Biomedical, Inc.
Mike Piccinino, CFA +1-443-213-0500
AlliquaBiomedical@westwicke.com
Alliqua, Inc. (NASDAQ:ALQA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliqua, Inc. (NASDAQ:ALQA)
Historical Stock Chart
From Apr 2023 to Apr 2024